T CTCL MIR-155 miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma CTCL

• 1. 用于治疗皮肤T细胞淋巴瘤（CTCL）的MIR-155抑制剂 [P] . 中国专利： CN108138180A . 2018-06-08
• 2. 一种miR-155/PEA15信号通路抑制剂在病理性心脏重构药物中的应用 [P] . 中国专利： CN112587662A . 2021-04-02
• 3. METHODS FOR TREATING CUTANEOUS T-CELL LYMPHOMA (CTCL) WITH MIR-155 INHIBITORS [P] . 欧洲知识产权局专利： EP3481404A4 . 2020-03-25

  机译： 用MIR-155抑制剂治疗皮肤T细胞淋巴瘤（CTCL）的方法

• 4. METHODS FOR TREATING CUTANEOUS T-CELL LYMPHOMA (CTCL) WITH MIR-155 INHIBITORS [P] . 美国专利： US2020276220A1 . 2020-09-03

  机译： 用MIR-155抑制剂治疗皮肤T细胞淋巴瘤（CTCL）的方法

• 5. MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL) [P] . CA2986949C . 2020-07-21

  机译： MIR-155抑制性T细胞淋巴瘤（CTCL）的抑制剂

• 1. Effect of inhibiting miR-155 expression on proliferation and migration of airway smooth muscle cell in patients with COPD [J] . Wei Wang, Si-Lin Zhao, Fu-Yuan Fan, 海南医科大学学报(英文版) . 2021,第010期
• 2. Effect of inhibiting miR-155 expression on proliferation and migration of airway smooth muscle cell in patients with COPD [J] . Wei Wang, Li Hu, Si-Lin Zhao, 海南医科大学学报（英文版） . 2021,第010期
• 3. Expression of miR-155 in nasopharyngeal carcinoma and its effect on proliferation of human nasopharyngeal carcinoma cells [J] . Xiao-Hong Chen, Dong-Mei Zeng, Jun-Zheng Li 海南医科大学学报（英文版） . 2019,第014期
• 4. Connecting the dots in cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant T cell proliferation via miR-155 [J] . LitvinovI.V., PehrK., SassevilleD. Cell cycle . 2013,第14期
• 5. Time to Next Treatment in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL) Receiving Mogamulizumab or Vorinostat: A MAVORIC Post-Hoc Analysis [J] . Sokol Lubomir, Kim Youn H., Ortiz-Romero Pablo L., Clinical lymphoma, myeloma & leukemia . 2019,第Suppla1期
• 6. Anti-CCR4 monoclonal antibody, mogamulizumab (Moga), demonstrates superior efficacy compared to vorinostat (Vor) in patients with previously treated cutaneous T-cell lymphoma (CTCL): results of the phase 3 MAVORIC study [J] . Kim Y. H., Bagot M., Rook A. H., The Journal of investigative dermatology. . 2018,第5a19期
• 7. Over-Expression of Circulating miR-21 and miR-155 in Plasma of Breast Cancer Patients [C] . Hyoung Soon Jang, Sungwoo Ahn, Jungho Kim, International Molecular Medicine Tri-Conference. . 2016
• 8. Inhibition of NFkappaB in cutaneous T-cell lymphoma HUT-78 cells by nuclear translocation of IkappaBalpha induced by proteasome inhibitors. [D] . Juvekar, Ashish. 2010
• 9. Connecting the dots in cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant T cell proliferation via miR-155 [O] . Ivan V Litvinov, Kevin Pehr, Denis Sasseville 2013
• 10. HLA-Identical Allogeneic Stem Cell Transplantation (alloSCT) for Patients With Primary Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Analysis of the Lymphoma Working Party of the European Blood and Marrow Transplantation Group (EBMT-LWP) [O] . Duarte R.F., Canals C., Onida F., 2009

• 1. Rituximab Improves Overall Survival in Patients Treated with CODOX-M/IVAC for Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and BL (BCL-U): A Single Center Experience and Review of the Literature [J] . A. Prica ,A. Pratzer ,M. Cheung . 癌症治疗（英文） . 2015,第1期
• 2. Atypical Cutaneous Lymphoproliferative Disorder: A Fatal Mimic of Cutaneous T-Cell Lymphoma in a Patient with HIV Infection [J] . Veronica Nguyen ,Russell Dorer ,David M. Aboulafia . 艾滋病（英文） . 2013,第1期
• 3. NK/T细胞淋巴瘤中miR-155的作用和机制 [C] . 马光宇 ,周凤灵 ,高玉环 . 第八届中国肿瘤内科大会、第三届中国肿瘤医师大会暨中国抗癌协会肿瘤临床化疗专业委员会2014年学术年会 . 2014
• 4. 非化疗和化疗治疗CTCL的效果比较 [A] . 李莹 . 2006